Trials / Recruiting
RecruitingNCT07241468
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD19/BCMA U CAR T | To evaluate the safety and effectiveness of anti-CD19/BCMA CAR T cells (KN3601) in patients with immune nephropathy. All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19/BCMA U CAR T cells infusion. |
Timeline
- Start date
- 2025-11-15
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
- First posted
- 2025-11-21
- Last updated
- 2026-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07241468. Inclusion in this directory is not an endorsement.